IL-2 Conjugate Selective Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using high-dose IL-2 for expanding Teff cell populations face challenges such as concomitant stimulation of Treg cells, leading to dampened anti-tumor responses and adverse events like eosinophilia and vascular leak syndrome, due to the engagement of IL-2R alpha chain-expressing cells.
Innovation Solution
Administration of IL-2 conjugates with a specific amino acid sequence modification, such as replacing the amino acid at position 64 with a PEG group, to selectively stimulate CD8+ and NK cells while minimizing Treg cell expansion and avoiding severe cytokine release syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose IL-2 is administered to expand Teff cell populations, then anti-tumor immune responses are enhanced, but Treg cell expansion occurs leading to dampened anti-tumor responses
Solution Approach 1:
The patent applies local quality by modifying the IL-2 molecule at a specific position (amino acid 64) to create a conjugate with altered binding properties. This localized modification enables selective engagement of IL-2R beta/gamma chains while avoiding alpha chain interaction, thereby achieving differential stimulation of Teff cells versus Treg cells. The modified IL-2 conjugate specifically activates CD8+ T cells and NK cells without the concomitant Treg activation that occurs with wild-type IL-2.
Solution Approach 2:
The patent employs parameter changes by altering the molecular structure of IL-2 through conjugation with PEG groups and amino acid modifications at position 64. This changes the pharmacological parameters of the cytokine, resulting in selective receptor engagement. The modified structure allows binding to IL-2R beta/gamma but not alpha, fundamentally changing the cellular response profile from mixed Teff/Treg activation to selective Teff/NK activation.
2Reliability
If high-dose IL-2 is administered to expand Teff cell populations, then anti-tumor responses are stimulated, but adverse events like eosinophilia and vascular leak syndrome occur
Solution Approach 1:
The patent applies the taking out principle by removing the harmful interaction between IL-2 and the IL-2R alpha chain, which mediates adverse events. Through structural modification at position 64 and PEG conjugation, the patent extracts or eliminates the binding affinity for alpha chain-expressing cells (eosinophils, endothelial cells), thereby preventing eosinophilia and vascular leak syndrome while preserving the beneficial Teff/NK cell activation through beta/gamma chain engagement.
3Productivity
If wild-type IL-2 is used to stimulate CD8+ and NK cells, then anti-tumor activity is enhanced, but concomitant Treg cell stimulation dampens the response
Solution Approach 1:
The patent applies segmentation by separating the IL-2 receptor engagement into distinct pathways: alpha chain engagement (which drives Treg activation and adverse events) and beta/gamma chain engagement (which drives Teff and NK activation). The modified IL-2 conjugate selectively engages beta/gamma chains while avoiding alpha chain interaction, effectively segmenting the cellular responses to achieve productive anti-tumor activity without harmful Treg counter-regulation.
Data Source
AI summary
Disclosed herein are methods and uses relating to administering IL-2 conjugates or methods useful for the treatment of one or more indications, such as the treatment of proliferative diseases. Also described herein are pharmaceutical compositions and kits comprising one or more of the IL-2 conjugates.